These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17071468)

  • 1. The evolving role of fluorodeoxyglucose positron emission tomography (FDG PET) in lymphoma: how do we reconcile conflicting results in the era of evidence-based medicine?
    Hicks RJ
    Leuk Lymphoma; 2006 Oct; 47(10):2008-10. PubMed ID: 17071468
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study.
    Fruchart C; Reman O; Le Stang N; Musafiri D; Cheze S; Macro M; Switsers O; Aide N; Liegard M; Levaltier X; Peny AM; Leporrier M; Bardet S
    Leuk Lymphoma; 2006 Dec; 47(12):2547-57. PubMed ID: 17169799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of FDG PET in the management of lymphoma: what is the evidence base?
    Kirby AM; Mikhaeel NG
    Nucl Med Commun; 2007 May; 28(5):335-54. PubMed ID: 17414883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VI. FDG-PET as a biomarker in lymphoma: from qualitative to quantitative analysis.
    Meignan M
    Hematol Oncol; 2015 Jun; 33 Suppl 1():38-41. PubMed ID: 26062052
    [No Abstract]   [Full Text] [Related]  

  • 5. FDG-PET interpretation in tonsillar lymphoma.
    Hsu CH; Lee TJ; Lee FP; Lee CM; Lin YH; Yang CM
    Acta Otolaryngol; 2007 Oct; 127(10):1118-20. PubMed ID: 17851897
    [No Abstract]   [Full Text] [Related]  

  • 6. Solitary splenic lymphoma detected with (18)F-FDG-PET/CT.
    Tamam M; Mulazimoglu M; Yavuz H; Aydin T; Filiz F; Ozpacaci T
    Hell J Nucl Med; 2011; 14(2):179-80. PubMed ID: 21761026
    [No Abstract]   [Full Text] [Related]  

  • 7. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
    Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
    J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma.
    Alinari L; Castellucci P; Elstrom R; Ambrosini V; Stefoni V; Nanni C; Berkowitz A; Tani M; Farsad M; Franchi R; Fanti S; Zinzani PL
    Leuk Lymphoma; 2006 Oct; 47(10):2096-101. PubMed ID: 17071482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
    Basu S; Li G; Bural G; Alavi A
    Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of brain FDG-PET in primary CNS lymphoma.
    Mohile NA; Deangelis LM; Abrey LE
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma.
    Adams HJA; Kwee TC
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):342-343. PubMed ID: 27783106
    [No Abstract]   [Full Text] [Related]  

  • 12. [FDG-PET for malignant lymphomas: important points for the hematologist].
    Nakamoto Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1351-8. PubMed ID: 19915342
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary cardiac lymphoma detected by 18F-FDG PET scan: a case report.
    Castelli JB; Alexandre L; Futuro G; Scanavacca M; Soares Júnior J
    J Nucl Cardiol; 2011 Oct; 18(5):974-7. PubMed ID: 21706271
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
    Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
    Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET imaging for response assessment in lymphoma: potential and limitations.
    Schöder H; Moskowitz C
    Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of FDG PET in the management of lymphoma: practical guidelines.
    Kirby AM; George Mikhaeel N
    Nucl Med Commun; 2007 May; 28(5):355-7. PubMed ID: 17414884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of F-18 FDG triple-head coincidence PET in the posttreatment evaluation of patients with lymphoma.
    Huić D; Mutvar A; Radman I; Grosev D; Labar B; Zuvić M; Dodig D; Aurer I; Nemet D
    Clin Nucl Med; 2006 May; 31(5):275-8. PubMed ID: 16622336
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma.
    Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji JB
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):344-345. PubMed ID: 27796542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.